DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jefferies - 4 Kaumil Gajrawala - 3 Gajrawala - 2 Fred Imbert - 2 Wells Fargo - 1 Roth - 1 Roblox - 1 Eric Handler - 1
Top related locs:
Monday's Boston U.S Tokyo Florida
Top related orgs:
CNBC - 3 Nvidia - 2 Jefferies - 2 Deutsche Bank - 1 JPMorgan - 1 Roth Capital Partners - 1 Barclays - 1 Boston Beer - 1

Search resuls for: "Gajrawala"


4 mentions found


☆ Tuesday's analyst calls: Nvidia earnings preview, gym stock gets an upgrade
  + stars: | 2024-05-14 | by ( Hakyung Kim Fred Imbert | Hakyung Kim | Fred Imbert | ) www.cnbc.com   time to read: +6 min
Deutsche Bank maintained a hold rating on Nvidia ahead of earnings next week, while Wells Fargo raised its price target. The firm downgraded shares to neutral from buy while lowering its price target to $35 from $55. He has a $850 price target on shares, indicating shares pulling back nearly 6% from Monday's close. The analyst raised his price target on the stock to $1,150 from $974, implying upside of more than 27%. He also raised his price target to $78 from $68, implying upside of 19% from Monday's close.
Persons: Wells Fargo, Roth, Roblox, Eric Handler, Handler, — Hakyung Kim, Tesla's, Elon Musk's, Tesla, Dan Levy, Levy, Hakyung Kim, Jefferies, Boston Beer, Samuel Adams, seltzer, Kaumil, Boston Beers, Seltzer, Gajrawala, Ross Seymore, NVDAs, Seymour, Wells Fargo's Aaron Rakers, Rahul Krotthapalli, Krotthapalli, Fred Imbert Organizations: CNBC, Nvidia, Deutsche Bank, JPMorgan, Roth Capital Partners, Barclays, Jefferies, Boston Beer, Boston, Deutsche, Fitness Locations: Monday's, Boston
☆ This overlooked corner of women's health could be a $350 billion market opportunity
  + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com   time to read: +5 min
The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.
Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo
☆ These tenbagger stocks are well liked by analysts and may rally even more
  + stars: | 2023-12-03 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Over the last 10 years of market turbulence, there haven't been very many stocks that have seen a more than 1,000% compound return. Fewer still of these "tenbaggers," companies that have multiplied in value 10 times, have sizeable upside expectations ahead. The average analyst still sees potential upside of 40%. Early last month, Jefferies began research coverage of Celsius with a buy rating, citing several growth opportunities that lie ahead. With a 10-year compound total return of nearly 13,000%, chipmaker Nvidia was also at the top of the list.
Persons: Jefferies, Kaumil Gajrawala, Fred Imbert Organizations: CNBC, Holdings, PepsiCo, Nvidia, Microsoft, Semiconductor, Broadcom, Builders, Neurocrine Biosciences Locations: Florida
☆ Monday's analyst calls: PC stock upgrade, Jefferies sees steady growth for consumer giant
  + stars: | 2023-11-13 | by ( Fred Imbert | ) www.cnbc.com   time to read: +5 min
Jefferies initiated Colgate-Palmolive with a buy rating, citing a stabilization in market share loss. The firm initiated coverage of DevOps stock on Monday with a buy rating and a $56 per share price target. "In short, we think GTLB is well positioned to gain share with its platform offering in a rapidly growing ~$40B DevSecOps target market," analyst Gray Powell said. The firm initiated coverage of the consumer giant with a buy rating and a $87 per share price target in a Sunday note. Analyst Kaumil Gajrawala said the company's market share losses from the height of the pandemic have stabilized, allowing Colgate-Palmolive to enter a period of steady growth.
Persons: Jefferies, Edward Jones, Oracle Edward Jones, Oracle's, Logan Purk, Purk, Brian Evans, Gray Powell, — Brian Evans, Bernstein, TripAdvisor, Richard Clarke, Asiya Merchant, Kaumil Gajrawala, Gajrawala Organizations: CNBC, Colgate, Palmolive, Citi, HP Inc, Oracle, Google, Amazon Web Services, Jefferies, ~$
0 next >>
Total: 4